CD8A and colorectal cancer: We observed increased IFNγ signaling, as previously reported in T-ALL PDX models after treatment with decitabine [5], and an increased CD8 level after decitabine therapy in the more sensitive T-LBL subgroup, in line with the previously reported increased activation and cytolytic activity of CD8+ T-cells after decitabine in colorectal cancers [59].